Carlos Gómez-Martín

Summary

Country: Spain

Publications

  1. doi request reprint A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer
    C Gomez-Martin
    GastroIntestinal Cancer Clinical Research Unit, Clinical Research Programme, Spanish National Cancer Centre CNIO, Fuenlabrada University Hospital, Camino del Molino 2, 28950 Madrid, Spain
    Invest New Drugs 31:390-8. 2013
  2. pmc HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer
    Carlos Gómez-Martín
    GastroIntestinal Cancer Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain
    J Clin Pathol 65:751-7. 2012
  3. doi request reprint Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen
    Carlos Gómez-Martín
    Gastrointestinal Cancer Unit, Medical Oncology Division, Doce de Octubre University Hospital, Avda de Cordoba s n, 28041, Madrid, Spain
    Clin Transl Oncol 14:689-97. 2012
  4. ncbi request reprint Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma
    Carlos Gómez-Martín
    GI Cancer Research Unit, Clinical Research Programme, National Cancer Research Centre, C Melchor Fernandez Almagro 3, Madrid, Spain
    Clin Transl Oncol 13:636-51. 2011
  5. doi request reprint Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation
    Carlos Gómez-Martín
    Gastrointestinal Cancer Unit, Spanish National Cancer Research Center, Fuenlabrada University Hospital, Camino del Molino 2, Fuenlabrada, Madrid, Spain
    Liver Transpl 18:45-52. 2012
  6. ncbi request reprint A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond
    Carlos Gómez-Martín
    Gastrointestinal Cancer Unit and Early Drug Development Unit, Medical Oncology Division, 12 de Octubre University Hospital, Madrid, Spain Laboratorio de Dianas Terapéuticas, Centro Integral Oncologico Clara Campal, Hospital Universitario Madrid Sanchinarro, Facultad de Medicina, Universidad San Pablo CEU, Madrid, Spain Electronic address
    Cancer Lett 351:30-40. 2014
  7. doi request reprint Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer
    Cristina Gravalos
    Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain
    Clin Transl Oncol 13:179-84. 2011
  8. ncbi request reprint SEOM clinical guidelines for the treatment of pancreatic cancer
    Carlos Gómez-Martín
    Servicio de Oncologia Medica, Hospital Universitario 12 de Octubre, Madrid, Spain
    Clin Transl Oncol 13:528-35. 2011
  9. ncbi request reprint Current status of mammalian target of rapamycin inhibitors in lung cancer
    Carlos Gómez-Martín
    Department of Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
    Clin Lung Cancer 7:S13-8. 2005

Detail Information

Publications9

  1. doi request reprint A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer
    C Gomez-Martin
    GastroIntestinal Cancer Clinical Research Unit, Clinical Research Programme, Spanish National Cancer Centre CNIO, Fuenlabrada University Hospital, Camino del Molino 2, 28950 Madrid, Spain
    Invest New Drugs 31:390-8. 2013
    ..Conclusions Sunitinib plus cisplatin 80 mg/m(2) and 5-FU 4,000 mg/m(2) were combinable and adverse events were manageable. The MTD of sunitinib was established as 25 mg/day on Schedule 2/1...
  2. pmc HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer
    Carlos Gómez-Martín
    GastroIntestinal Cancer Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain
    J Clin Pathol 65:751-7. 2012
    ..To study the HER2 gene amplification or overexpression in patients with advanced gastric cancer (GC) and their association with patient characteristics and patient survival...
  3. doi request reprint Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen
    Carlos Gómez-Martín
    Gastrointestinal Cancer Unit, Medical Oncology Division, Doce de Octubre University Hospital, Avda de Cordoba s n, 28041, Madrid, Spain
    Clin Transl Oncol 14:689-97. 2012
    ..Hand-foot syndrome (HFS) is a limiting toxicity of capecitabine, which is not life-threatening but could compromise capecitabine efficacy...
  4. ncbi request reprint Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma
    Carlos Gómez-Martín
    GI Cancer Research Unit, Clinical Research Programme, National Cancer Research Centre, C Melchor Fernandez Almagro 3, Madrid, Spain
    Clin Transl Oncol 13:636-51. 2011
    ..Any laboratories which do not meet the minimum standards set out in the guidelines must make every effort to achieve compliance...
  5. doi request reprint Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation
    Carlos Gómez-Martín
    Gastrointestinal Cancer Unit, Spanish National Cancer Research Center, Fuenlabrada University Hospital, Camino del Molino 2, Fuenlabrada, Madrid, Spain
    Liver Transpl 18:45-52. 2012
    ..The toxicity and efficacy need to be further evaluated in randomized controlled studies for this combination to be considered a valid option...
  6. ncbi request reprint A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond
    Carlos Gómez-Martín
    Gastrointestinal Cancer Unit and Early Drug Development Unit, Medical Oncology Division, 12 de Octubre University Hospital, Madrid, Spain Laboratorio de Dianas Terapéuticas, Centro Integral Oncologico Clara Campal, Hospital Universitario Madrid Sanchinarro, Facultad de Medicina, Universidad San Pablo CEU, Madrid, Spain Electronic address
    Cancer Lett 351:30-40. 2014
    ..This article reviews the current state of HER2 in gastric cancer focusing on diagnostic and anti-HER2 targeted treatment issues and the role of trastuzumab in localized disease, and its combination or integration with new therapies. ..
  7. doi request reprint Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer
    Cristina Gravalos
    Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain
    Clin Transl Oncol 13:179-84. 2011
    ..We conducted a multicentre phase II trial to evaluate trastuzumab in combination with cisplatin in patients with untreated HER2-positive advanced gastric or GEJ cancer...
  8. ncbi request reprint SEOM clinical guidelines for the treatment of pancreatic cancer
    Carlos Gómez-Martín
    Servicio de Oncologia Medica, Hospital Universitario 12 de Octubre, Madrid, Spain
    Clin Transl Oncol 13:528-35. 2011
    ..In recent years new chemotherapy combinations and targeted agents have demonstrated significant antitumoral activity, increasing the armamentarium that can be used against this lethal disease...
  9. ncbi request reprint Current status of mammalian target of rapamycin inhibitors in lung cancer
    Carlos Gómez-Martín
    Department of Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
    Clin Lung Cancer 7:S13-8. 2005
    ....